The enthusiasm about the application of SGLT2 inhibitors in cardiovascular medicine should further promote the closer collaborations among scientists from basic research labs and clinical medicine. https://t.co/tNgMSUkmSm
RT @KardiologieWien: @ZelnikerThomas, joining us at @MedUni_Wien after spending several years @TIMIStudyGroup and Dr. Eugene Braunwald prov…
RT @KardiologieWien: @ZelnikerThomas, joining us at @MedUni_Wien after spending several years @TIMIStudyGroup and Dr. Eugene Braunwald prov…
RT @KardiologieWien: @ZelnikerThomas, joining us at @MedUni_Wien after spending several years @TIMIStudyGroup and Dr. Eugene Braunwald prov…
RT @KardiologieWien: @ZelnikerThomas, joining us at @MedUni_Wien after spending several years @TIMIStudyGroup and Dr. Eugene Braunwald prov…
RT @KardiologieWien: @ZelnikerThomas, joining us at @MedUni_Wien after spending several years @TIMIStudyGroup and Dr. Eugene Braunwald prov…
RT @KardiologieWien: @ZelnikerThomas, joining us at @MedUni_Wien after spending several years @TIMIStudyGroup and Dr. Eugene Braunwald prov…
RT @KardiologieWien: @ZelnikerThomas, joining us at @MedUni_Wien after spending several years @TIMIStudyGroup and Dr. Eugene Braunwald prov…
@ZelnikerThomas, joining us at @MedUni_Wien after spending several years @TIMIStudyGroup and Dr. Eugene Braunwald provide an overview of the cardio-metabolic-renal benefits of SGLT2i in @JACCJournals Part 1: https://t.co/kGeyh7Kz6L Part 2: https://t.co/
RT @krychtiukmd: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors - one of two @JACCJournals state of…
Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors https://t.co/1Ym6ARnQXh
RT @JACCJournals: ICYMI: The latest #JACC State-of-the-Art Review is a two-parter from Drs. @ZelnikerThomas & Eugene Braunwald on the cardi…
@SVCardio @ValleAlfonso @secardiologia @redGDPS @SociedadSeedo @SEMERGENap @IICOMV @COMAlicante @Cardio_delaGuia @lualmenar @JuliaSellerm @IC_LaFe @CristobMorales @moreno_perez_o @SVNefro Este es el articulo que comentamos en el podcast: https://t.co/GaEx8
RT @JACCJournals: ICYMI: The latest #JACC State-of-the-Art Review is a two-parter from Drs. @ZelnikerThomas & Eugene Braunwald on the cardi…
【総説】SGLT2阻害薬の心腎効果の臨床的利点 https://t.co/OitWvN0igm
RT @JACCJournals: ICYMI: The latest #JACC State-of-the-Art Review is a two-parter from Drs. @ZelnikerThomas & Eugene Braunwald on the cardi…
RT @JACCJournals: ICYMI: The latest #JACC State-of-the-Art Review is a two-parter from Drs. @ZelnikerThomas & Eugene Braunwald on the cardi…
RT @JACCJournals: ICYMI: The latest #JACC State-of-the-Art Review is a two-parter from Drs. @ZelnikerThomas & Eugene Braunwald on the cardi…
RT @JACCJournals: ICYMI: The latest #JACC State-of-the-Art Review is a two-parter from Drs. @ZelnikerThomas & Eugene Braunwald on the cardi…
RT @JACCJournals: ICYMI: The latest #JACC State-of-the-Art Review is a two-parter from Drs. @ZelnikerThomas & Eugene Braunwald on the cardi…
RT @JACCJournals: ICYMI: The latest #JACC State-of-the-Art Review is a two-parter from Drs. @ZelnikerThomas & Eugene Braunwald on the cardi…
RT @JACCJournals: ICYMI: The latest #JACC State-of-the-Art Review is a two-parter from Drs. @ZelnikerThomas & Eugene Braunwald on the cardi…
RT @JACCJournals: ICYMI: The latest #JACC State-of-the-Art Review is a two-parter from Drs. @ZelnikerThomas & Eugene Braunwald on the cardi…
RT @JACCJournals: ICYMI: The latest #JACC State-of-the-Art Review is a two-parter from Drs. @ZelnikerThomas & Eugene Braunwald on the cardi…
RT @JACCJournals: ICYMI: The latest #JACC State-of-the-Art Review is a two-parter from Drs. @ZelnikerThomas & Eugene Braunwald on the cardi…
RT @JACCJournals: ICYMI: The latest #JACC State-of-the-Art Review is a two-parter from Drs. @ZelnikerThomas & Eugene Braunwald on the cardi…
RT @JACCJournals: ICYMI: The latest #JACC State-of-the-Art Review is a two-parter from Drs. @ZelnikerThomas & Eugene Braunwald on the cardi…
RT @JACCJournals: ICYMI: The latest #JACC State-of-the-Art Review is a two-parter from Drs. @ZelnikerThomas & Eugene Braunwald on the cardi…
RT @JACCJournals: ICYMI: The latest #JACC State-of-the-Art Review is a two-parter from Drs. @ZelnikerThomas & Eugene Braunwald on the cardi…
Good SGLT2i paper from the master, Eugene Braunwald
RT @JACCJournals: ICYMI: The latest #JACC State-of-the-Art Review is a two-parter from Drs. @ZelnikerThomas & Eugene Braunwald on the cardi…
Fantastic! #SGLT2I #cardiorenal #JACC a must read
RT @JACCJournals: ICYMI: The latest #JACC State-of-the-Art Review is a two-parter from Drs. @ZelnikerThomas & Eugene Braunwald on the cardi…
RT @JACCJournals: ICYMI: The latest #JACC State-of-the-Art Review is a two-parter from Drs. @ZelnikerThomas & Eugene Braunwald on the cardi…
ICYMI: The latest #JACC State-of-the-Art Review is a two-parter from Drs. @ZelnikerThomas & Eugene Braunwald on the cardiorenal effects of #SGLT2I. 1️⃣: Mechanisms of Effects: https://t.co/P8f3ECsbWC 2️⃣: Clinical Benefit Effects: https://t.co/Odxo7x
RT @HanCardiomd: Ongoing trials are addressing the role of SGLT2i in patient with HF and preserved ejection fraction and chronic kidney dis…
RT @HanCardiomd: Ongoing trials are addressing the role of SGLT2i in patient with HF and preserved ejection fraction and chronic kidney dis…
RT @HanCardiomd: Ongoing trials are addressing the role of SGLT2i in patient with HF and preserved ejection fraction and chronic kidney dis…
RT @HanCardiomd: Ongoing trials are addressing the role of SGLT2i in patient with HF and preserved ejection fraction and chronic kidney dis…
RT @HanCardiomd: Ongoing trials are addressing the role of SGLT2i in patient with HF and preserved ejection fraction and chronic kidney dis…
RT @HanCardiomd: Ongoing trials are addressing the role of SGLT2i in patient with HF and preserved ejection fraction and chronic kidney dis…
RT @krychtiukmd: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors - one of two @JACCJournals state of…
RT @krychtiukmd: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors - one of two @JACCJournals state of…
RT @nossikoff: great photo @GiuseppeGalati_ @ShelleyZieroth
great photo @GiuseppeGalati_ @ShelleyZieroth
RT @HanCardiomd: Ongoing trials are addressing the role of SGLT2i in patient with HF and preserved ejection fraction and chronic kidney dis…
Ongoing trials are addressing the role of SGLT2i in patient with HF and preserved ejection fraction and chronic kidney disease,with and without T2DM https://t.co/8r0mUhqSTt @ACCinTouch @ACCMass @escardio @lamcardio @ErinMichos @DLBHATTMD @AnastasiaSMihai @
RT @ZelnikerThomas: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors https://t.co/SelPn0ZEjT https://t.…
RT @ZelnikerThomas: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors https://t.co/SelPn0ZEjT https://t.…
RT @cristinatejerap: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors | JACC: Journal of the American C…
RT @ZelnikerThomas: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors https://t.co/SelPn0ZEjT https://t.…
RT @ZelnikerThomas: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors https://t.co/SelPn0ZEjT https://t.…
RT @ZelnikerThomas: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors https://t.co/SelPn0ZEjT https://t.…
RT @ZelnikerThomas: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors https://t.co/SelPn0ZEjT https://t.…
RT @ZelnikerThomas: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors https://t.co/SelPn0ZEjT https://t.…
RT @cristinatejerap: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors | JACC: Journal of the American C…
RT @ZelnikerThomas: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors https://t.co/SelPn0ZEjT https://t.…
RT @ZelnikerThomas: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors https://t.co/SelPn0ZEjT https://t.…
RT @ZelnikerThomas: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors https://t.co/SelPn0ZEjT https://t.…
RT @juanquiles: Estupenda revisión en @JACCJournals sobre los efectos cardiorenales de los ISGLT-2: 👉 Mecanismos: https://t.co/cj9pLns5aQ…
Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors https://t.co/SelPn0ZEjT https://t.co/7Ol9hnpqQb
RT @krychtiukmd: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors - one of two @JACCJournals state of…
RT @juanquiles: Estupenda revisión en @JACCJournals sobre los efectos cardiorenales de los ISGLT-2: 👉 Mecanismos: https://t.co/cj9pLns5aQ…
RT @krychtiukmd: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors - one of two @JACCJournals state of…
RT @krychtiukmd: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors - one of two @JACCJournals state of…
RT @krychtiukmd: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors - one of two @JACCJournals state of…
RT @krychtiukmd: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors - one of two @JACCJournals state of…
RT @krychtiukmd: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors - one of two @JACCJournals state of…
Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors | JACC https://t.co/ZhKw1xGIxy https://t.co/Byn1Y1IAFg
Beneficio clínico de los efectos cardiorenales de los inhibidores del cotransportador 2 de sodio y glucosa | JACC: Revista del Colegio Americano de Cardiología #iSGLT2
RT @cristinatejerap: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors | JACC: Journal of the American C…
Another important review on SGLT2 inhibitors! This class should be more prescribed !! #cardiotwitter
RT @pabeda1: Thanks for sharing, @krychtiukmd. A review by Zelniker and Braunwald is something precious, must be spread over #cardiotwitter…
RT @cristinatejerap: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors | JACC: Journal of the American C…
RT @juanquiles: Estupenda revisión en @JACCJournals sobre los efectos cardiorenales de los ISGLT-2: 👉 Mecanismos: https://t.co/cj9pLns5aQ…
RT @CardioIAN: @CardioIAN @MihaiTrofenciuc
@CardioIAN @MihaiTrofenciuc
RT @krychtiukmd: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors - one of two @JACCJournals state of…
RT @cristinatejerap: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors | JACC: Journal of the American C…
Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors | JACC: Journal of the American College of Cardiology https://t.co/V6FXftOyFp
Estupenda revisión en @JACCJournals sobre los efectos cardiorenales de los ISGLT-2: 👉 Mecanismos: https://t.co/cj9pLns5aQ 👉 Beneficios clínicos: https://t.co/AI4pfDzm2l #cardiotwitter
RT @krychtiukmd: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors - one of two @JACCJournals state of…
RT @krychtiukmd: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors - one of two @JACCJournals state of…
Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review https://t.co/BHIQOqPn2h
RT @krychtiukmd: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors - one of two @JACCJournals state of…
Thanks for sharing, @krychtiukmd. A review by Zelniker and Braunwald is something precious, must be spread over #cardiotwitter !
RT @krychtiukmd: Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors - one of two @JACCJournals state of…
Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors - one of two @JACCJournals state of the art reviews on SGLT2i by @ZelnikerThomas, former @TIMIStudyGroup now @MedUni_Wien and the legend Prof Braunwald https://t.co/lw3